Pharmaceuticals
Faculty of Medicine Siriraj Hospital and Dhulikhel Hospital commemorate 15 years of collaborative relationship
BANGKOK, June 17, 2024 /PRNewswire/ -- In 2024, Thai-Nepalese bilateral relations reached a new milestone as the Faculty of Medicine Siriraj Hospital at Mahidol University inThailand and Dhulikhel Hospital at Kathmandu University inNepal celebrated the 15th anniversary of their esteemed partnersh...
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
* Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other thanChina and a few other areas. * Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential m...
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
SAN FRANCISCO and SUZHOU, China, June 14, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology ...
Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China
SAINT-CLOUD, France, June 13, 2024 /PRNewswire/ -- Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from the Chinese Company Jiangsu Anbison Pharmaceutical. Leader in essential medicines for cen...
Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that th...
Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
SAN FRANCISCO and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
Ansell Recognized with the Frost & Sullivan 2024 Global Company of the Year Award for Revolutionizing Workplace Safety and Promoting Sustainability
Ansell is committed to ensuring the safety and well-being of workers worldwide with an extensive range of safety solutions that meet the specific needs of clinicians and healthcare providers. SAN ANTONIO, June 12, 2024 /PRNewswire/ -- Frost & Sullivan recently researched and conducted a review o...
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...
Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma
140 patients have been recruited at sites in Spain, Italy, France and United Kingdom. The open readout of the trial is expected by late 2024. Laminar aims to submit regulatory filings or conditional marketing authorization by early 2025. PALMA DE MALLORCA, Spain, June 12, 2024 /PRNewswire/ -- Lam...
Chengdu's influence being felt across the world
CHENGDU, China, June 11, 2024 /PRNewswire/ -- Openness is a defining characteristic of contemporaryChina. In recent years, Chengdu, capital of Sichuan province, has used its location as a key hub in the Belt and Road Initiative and as a starting point of the ancient Southern Silk Road. By deepen...
Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE
SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) ofChina'...
Element Six and Orbray partner to deliver the world's highest quality wafer-scale single crystal synthetic diamond
GRESHAM, Ore. and TOKYO, June 11, 2024 /PRNewswire/ -- Element Six
Octapharma's continuing dedication to improving the lives of people with rare bleeding disorders to be showcased at ISTH 2024
* Octapharma to present new clinical and scientific findings for wilate® and Nuwiq® at the upcoming ISTH 2024 Congress * New data and clinical study developments to be showcased in seven oral presentations, two posters and two Supported Symposia LACHEN, Switzerland, June 10, 2024 /PRNewswire/...
ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal
SEOUL, South Korea, June 7, 2024 /PRNewswire/ -- Dear Fellow Shareholders, ILJIN SNT Co., Ltd. ("ILJIN") is a long-standing investor of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), and, together with its affiliates, currently holds more than 5% of Aurinia's common stock. As one of...
IONETIX Produces First Batch of Actinium-225
LANSING, Mich., June 7, 2024 /PRNewswire/ -- IONETIX, a leading cyclotron technology innovator, isotope producer, and radiopharmaceutical manufacturer, announced today the successful production of Actinium-225 ("Ac-225") at its isotope manufacturing facility located inLansing, Michigan. This fir...
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody responses and contributes toimproved sustained HBsAg loss in PEG-IFNa-t...
Clinical Data of First-in-class HBV-specificTCR T Cell Therapy (SCG101) Presented at ESAL Congress Showing Improved Overall Survival in HBV-related Hepatocellular Carcinoma
SINGAPORE, June 7, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced that clinical data from its first-in-class autologous hepatitis B virus (HBV)-specific...
MLB Announces IND Approval by US FDA to Initiate Phase 1 Trial of TML-6, a New Era Multi-Target Drug for the Treatment of Alzheimer's Disease
TAINAN, June 7, 2024 /PRNewswire/ -- MLB (Merry Life Biomedical Company, Ltd.,
Taiwan: https://www.tmlbio.com/
NDA for Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Filed in Japan for Treating Alzheimer's Dementia
TOKYO, June 6, 2024 /PRNewswire/ -- Luye Pharma Group announced that its partner Towa Pharmaceutical Co., Ltd. (Towa) has filed a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) inJapan for the Rivastigmine Twice Weekly Transdermal Patch for treating mild to modera...
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 302 media titles]
2025-01-23 09:00Agoda Expands Its Eco Deals Program Pledging Up to $1.5 Million to Fund Critical Conservation Projects Across 10 Asian Markets in Partnership with WWF
[Picked up by 292 media titles]
2025-01-23 09:00Sephora Unveils Its First Film, "Beauty & Belonging" Celebrating Diversity and Authenticity
[Picked up by 287 media titles]
2025-01-24 08:00